Suppr超能文献

2系豚鼠中T细胞参与10号线肿瘤免疫的过继转移。

T-cell involvement in adoptive transfer of line 10 tumor immunity in strain 2 guinea pigs.

作者信息

de Jong W H, Steerenberg P A, van de Plas M M, Kruizinga W, Ruitenberg J

出版信息

J Natl Cancer Inst. 1985 Sep;75(3):483-9.

PMID:3875751
Abstract

Several aspects of adoptive transfer of tumor immunity were studied in the line 10 hepatocarcinoma in the syngeneic Sewall-Wright strain 2 guinea pig. In particular, the need for cooperation between donor and recipient T-cells was investigated. Donor immune spleen cells remained immunologically capable of inducing tumor rejection for at least 160 days after adoptive transfer. Irradiated (1,000 rad) or mitomycin-treated immune spleen cells lacked tumor-rejection activity, which is indicative of the necessity for in vivo proliferation after adoptive transfer of immunity. Furthermore, adoptive transfer of tumor immunity was abrogated after treatment of the line 10 immune spleen cells with rabbit anti-guinea pig-thymocyte serum (ATS) plus complement. The role of recipient T-cells was investigated in strain 2 guinea pigs which were T-cell depleted by thymectomy, irradiation, and bone marrow reconstitution (T-XBM animals). Severe suppression of T-cell activity was present at 2 and 6 weeks after irradiation and bone marrow reconstitution. At 10 weeks nonspecific T-cell activity was partially restored. The induction of antigen-specific responses, measured by delayed-type hypersensitivity skin testing in vivo and antigenic stimulation in vitro, was suppressed at 2 weeks after irradiation and bone marrow reconstitution. Additional in vivo treatment of T-XBM animals with a rabbit ATS improved the T-cell depletion only moderately. Tumor growth and tumor rejection after adoptive transfer of immunity were equal in normal and T-cell-deprived recipient animals, thus indicating that recipient T-cells are not needed for tumor rejection after adoptive transfer of line 10 tumor immunity.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

在同基因的休厄尔-赖特2号豚鼠品系的10型肝癌中,研究了肿瘤免疫过继转移的几个方面。特别研究了供体和受体T细胞之间合作的必要性。供体免疫脾细胞在过继转移后至少160天仍具有诱导肿瘤排斥的免疫能力。经照射(1000拉德)或丝裂霉素处理的免疫脾细胞缺乏肿瘤排斥活性,这表明免疫过继转移后体内增殖的必要性。此外,用兔抗豚鼠胸腺细胞血清(ATS)加补体处理10型免疫脾细胞后,肿瘤免疫的过继转移被消除。在通过胸腺切除、照射和骨髓重建使T细胞耗竭的2号豚鼠(T-XBM动物)中研究了受体T细胞的作用。照射和骨髓重建后2周和6周时存在严重的T细胞活性抑制。在10周时,非特异性T细胞活性部分恢复。通过体内迟发型超敏皮肤试验和体外抗原刺激测量的抗原特异性反应的诱导在照射和骨髓重建后2周时受到抑制。用兔ATS对T-XBM动物进行额外的体内处理仅适度改善了T细胞耗竭情况。正常受体动物和T细胞缺失受体动物在免疫过继转移后的肿瘤生长和肿瘤排斥情况相同,因此表明在10型肿瘤免疫过继转移后肿瘤排斥不需要受体T细胞。(摘要截短至250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验